NeoGenomics financials
$18.74−2.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $727.3M | $660.6M | $591.6M | $509.7M | $484.3M | $444.4M | $408.8M | $276.7M | $240.3M | $231.8M |
| Gross profit | $314.3M | $290.1M | $244.6M | $187.9M | $187.1M | $185.9M | $196.8M | $127.3M | $102.0M | $98.1M |
| Gross margin | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% | 48.1% | 46.0% | 42.4% | 42.3% |
| Operating income | -$115.9M | -$92.1M | -$107.7M | -$157.6M | -$118.8M | -$14.0M | $13.0M | $10.0M | $4.0M | $2.2M |
| Net income | -$108.0M | -$78.7M | -$88.0M | -$144.3M | -$8.3M | $4.2M | $8.0M | $6.1M | -$10.9M | -$30.8M |
| Net margin | −14.9% | −11.9% | −14.9% | −28.3% | −1.7% | 0.9% | 2.0% | 2.2% | −4.6% | −13.3% |
| Diluted EPS | $-0.84 | $-0.62 | $-0.70 | $-1.16 | $-0.07 | $0.04 | $0.08 | $0.07 | $-0.14 | $-0.40 |
| EBITDA | -$20.3M | -$12.9M | -$24.1M | -$83.7M | -$65.4M | $21.7M | $43.3M | $31.8M | $26.6M | $28.8M |
| Operating cash flow | $5.2M | $7.0M | -$2.0M | -$66.0M | -$26.7M | $1.5M | $23.4M | $44.8M | $18.0M | $21.5M |
| Free cash flow | -$21.8M | -$34.0M | -$30.7M | -$96.9M | -$90.9M | -$27.6M | $3.3M | $30.5M | $4.3M | $13.9M |
| Diluted shares | 128.1M | 126.7M | 125.5M | 124.2M | 120.0M | 111.8M | 103.6M | 91.6M | 79.4M | 77.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $159.6M | $367.0M | $342.5M | $263.2M | $316.8M | $228.7M |
| Short-term investments | $0.00 | $19.8M | $72.7M | $174.8M | $198.6M | $67.5M |
| Total debt | $341.9M | $541.1M | $538.2M | $535.4M | $533.6M | $171.9M |
| Total assets | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B | $988.3M |
| Total liabilities | $523.3M | $735.7M | $739.7M | $742.0M | $761.5M | $294.0M |
| Shareholders' equity | $836.6M | $902.3M | $941.5M | $998.0M | $1.11B | $694.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology